Repligen
RGEN
#1868
Rank
โ‚ฌ9.85 B
Marketcap
155,17ย โ‚ฌ
Share price
6.13%
Change (1 day)
21.28%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of June 2026 : โ‚ฌ0.61 Billion

According to Repligen 's latest financial reports the company's total debt is โ‚ฌ0.61 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2026)

Total debt by year

Year Total debt Change
2025-12-31โ‚ฌ0.58 B-10.94%
2024-12-31โ‚ฌ0.65 B2.42%
2023-12-31โ‚ฌ0.64 B63.3%
2022-12-31โ‚ฌ0.39 B21.99%
2021-12-31โ‚ฌ0.32 B44.35%
2020-12-31โ‚ฌ0.22 B-4.74%
2019-12-31โ‚ฌ0.23 B159.84%
2018-12-31โ‚ฌ90.46 M9.36%
2017-12-31โ‚ฌ82.71 M-8.67%
2016-12-31โ‚ฌ90.57 M
2005-03-31โ‚ฌ0.09 M34.1%
2004-03-31โ‚ฌ0.06 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
โ‚ฌ56.39 B 9,046.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
โ‚ฌ37.97 B 6,058.11%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
โ‚ฌ17.09 B 2,672.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ40.20 B 6,420.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
โ‚ฌ17.25 M-97.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
โ‚ฌ0.26 B-56.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
โ‚ฌ0.35 B-41.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
โ‚ฌ0.25 B-58.16%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
โ‚ฌ3.75 B 508.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
โ‚ฌ2.70 B 338.20%๐Ÿ‡บ๐Ÿ‡ธ USA